Full-Time

Head of Legal

Confirmed live in the last 24 hours

Orca Bio

Orca Bio

51-200 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Compensation Overview

$200k - $275kAnnually

+ Pre-IPO Equity

Senior, Expert

Remote in USA

Category
Legal
Legal & Compliance
Requirements
  • JD degree from an accredited law school
  • 7-10+ years of experience in corporate law
  • Current admission to any state bar in good standing (California preferred)
  • Life Science industry experience
  • Experience with strategic and financing transactions, including IPO, equity, and/or M&A
Responsibilities
  • Advise the Company on strategic and financing transactions, including managing due diligence, drafting and negotiation of transaction documents, and closing
  • Draft, review, and negotiate general and sophisticated corporate and commercial agreements, including licenses, manufacturing, confidentiality, material transfer, consulting, employment, vendor, services, purchasing, outsourcing, software, research, licensing, clinical trial, and data-related agreements
  • Advise the Company on regulatory compliance matters, including FDA regulations, HIPAA regulations, and export controls
  • Represent the Company in regulatory proceedings and litigation
  • Provide general advice and guidance on legal best practices as we approach product approval / launch
  • Efficiently source, manage, and direct outside counsel

Orca Bio operates in the biotechnology field, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.

Company Stage

Series D

Total Funding

$186.8M

Headquarters

Menlo Park, California

Founded

2016

Growth & Insights
Headcount

6 month growth

12%

1 year growth

16%

2 year growth

41%
Simplify Jobs

Simplify's Take

What believers are saying

  • Orca-T demonstrated 87% relapse-free survival in a Phase 1b/2 trial.
  • FDA's expedited approval pathways could accelerate Orca Bio's market entry.
  • Advancements in gene editing enhance the efficacy of Orca Bio's cell therapies.

What critics are saying

  • Emerging competition from BlueRock Therapeutics in stem cell therapies.
  • Aspen Neuroscience's advancements in personalized stem cell therapies pose a threat.
  • Competitors' focus on iPSC-derived therapies may overshadow Orca Bio's offerings.

What makes Orca Bio unique

  • Orca Bio focuses on high-precision cell therapies for cancer and autoimmune diseases.
  • Their lead product, Orca-T, shows promising relapse-free survival rates in clinical trials.
  • Orca Bio's therapies aim to replace diseased blood and immune systems with healthy ones.

Help us improve and share your feedback! Did you find this helpful?